NO-aspirin: mechanism of action and gastrointestinal safety
- 1 May 2003
- journal article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 35, S9-S19
- https://doi.org/10.1016/s1590-8658(03)00047-1
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- NCX-4016 (NO-Aspirin) Inhibits Lipopolysaccharide-Induced Tissue Factor Expression In VivoCirculation, 2002
- NCX‐4016, a nitric oxide‐releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial functionThe FASEB Journal, 2002
- Does nitric oxide modulate mitochondrial energy generation and apoptosis?Nature Reviews Molecular Cell Biology, 2002
- NCX4016 (NO‐Aspirin) has multiple inhibitory effects in LPS‐stimulated human monocytesBritish Journal of Pharmacology, 2001
- NitrosylationCell, 2001
- Vasorelaxant effects of a nitric oxide‐releasing aspirin derivative in normotensive and hypertensive ratsBritish Journal of Pharmacology, 2001
- Caspases: Enemies WithinScience, 1998
- Cytokine - Processing Enzymes: Stopping the cutsCurrent Biology, 1995
- Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomachLife Sciences, 1989
- Randomised trial of prophylactic daily aspirin in British male doctorsBMJ, 1988